Virological Features and Clinical Manifestations Associated with Human Metapneumovirus: A New Paramyxovirus Responsible for Acute Respiratory‐Tract Infections in All Age Groups

Guy Boivin, Yacine Abed, Gilles Pelletier, Louisette Ruel, Danielle Moisan, Stéphanie Côté, Teresa C. T. Peret, Dean D. Erdman, Larry J. Anderson

The Journal of Infectious Diseases · 2002 · 605 citations · 13 references

DOIFull text

Open access

Concepts

TL;DR

The study retrospectively examined HMPV virology and clinical features in Canadian hospitalized patients with respiratory illnesses from 1993 onward. Thirty‑eight previously unidentified respiratory viruses isolated from LLC‑MK2 cells were confirmed as HMPV, clustering into two phylogenetic groups, and the virus was found to cause severe lower‑respiratory‑tract infections in young children, the elderly, and immunocompromised patients, with high rates of pneumonitis and bronchiolitis in children and bronchitis/bronchospasm in the elderly.

Abstract

The virological features and clinical findings associated with the new human metapneumovirus (HMPV) were examined retrospectively in Canadian patients hospitalized for various respiratory conditions since 1993. Thirty-eight previously unidentified respiratory viruses isolated from rhesus monkey kindey (LLC-MK2) cells were found to be positive for HMPV by reverse-transcription polymerase chain reaction, and those strains clustered in 2 phylogenetic groups. Children aged <5 years and elderly subjects aged >65 years represented 35.1% and 45.9% of the HMPV-infected cases, respectively. In hospitalized children, the most frequent diagnoses were pneumonitis (66.7%) and bronchiolitis (58.3%), whereas bronchitis and/or bronchospasm (60%) and pneumonitis (40%) were most commonly seen in elderly subjects. Of the 15 patients with pneumonitis, 4 (26.7%) had immunosuppressive conditions and 6 (40%) were infants aged <15 months. These findings suggest that HMPV can be associated with severe lower-respiratory-tract infections in very young children, the elderly, and immunocompromised patients.

References

13